MedTrace Logo

Effect of Erythropoiesis-Stimulating Agent Therapy in Patients Receiving Palliative Care of Chronic Kidney Disease

NCT03427801 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 78

Last updated 2019-01-31

No results posted yet for this study

Summary

An observational study to evaluate the effect of erythropoiesis-stimulating agents in treating anaemia of renal disease among adult patients receive palliative care instead of dialysis.

Conditions

  • Anemia of Chronic Kidney Disease

Interventions

DRUG

Erythropoiesis-Stimulating Agent

erythropoiesis-stimulating agent: Mircera or Darbepoietin

Sponsors & Collaborators

  • Chinese University of Hong Kong

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-01
Primary Completion
2018-12-01
Completion
2018-12-30
FDA Drug
Yes

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03427801 on ClinicalTrials.gov